### **MAJOR ARTICLE**

1

9

10

20

- 2 Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 &
- 3 Omicron variant in adults who received two doses of inactivated vaccine
- 4 Nancy H. L. Leung\*1, Samuel M. S. Cheng<sup>1</sup>, Mario Martín-Sánchez<sup>1</sup>, Niki Y. M. Au<sup>1</sup>, Yvonne
- 5 Y. Ng<sup>1</sup>, Leo L. H. Luk<sup>1</sup>, Karl C. K. Chan<sup>1</sup>, John K. C. Li<sup>1</sup>, Yonna W. Y. Leung<sup>1</sup>, Leo C. H.
- 6 Tsang<sup>1</sup>, Sara Chaothai<sup>1</sup>, Kelvin K. H. Kwan<sup>1</sup>, Dennis K. M. Ip<sup>1</sup>, Leo L. M. Poon<sup>1,3,4</sup>, Gabriel M.
- 7 Leung<sup>1,2</sup>, J. S. Malik Peiris<sup>†1,3,4</sup>, Benjamin J. Cowling<sup>\*†1,2</sup>
- 8 †Joint senior authors with equal contribution

#### **Affiliations:**

- <sup>1</sup>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public
- Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special
- 13 Administrative Region, China.
- <sup>2</sup>Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong
- 15 Kong Special Administrative Region, China.
- <sup>3</sup>HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The
- 17 University of Hong Kong; Hong Kong Special Administrative Region, China.
- <sup>4</sup>Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong Kong
- 19 Special Administrative Region, China.

21	Summary: (40 words)
22	In this open label trial of Chinese adults aged ≥30 years who received two doses of inactivated
23	COVID-19 vaccine 6 months earlier, third-dose mRNA vaccine substantially improved antibody
24	levels against the ancestral virus and Omicron variant with well-tolerated safety profile.
25	
26	Word count (abstract): 250
27	Word count (main text): 2,996
28	
29	*Corresponding authors: <a href="mailto:bcowling@hku.hk">bcowling@hku.hk</a> and <a href="mailto:leungnan@hku.hk">leungnan@hku.hk</a>
20	

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

**ABSTRACT Background:** Limited data exist on antibody responses to mixed vaccination strategies involving inactivated COVID-19 vaccines, particularly in the context of emerging variants. **Methods:** We conducted an open label trial of a third vaccine dose of an mRNA vaccine (BNT162b2, Fosun Pharma/BioNTech) in adults aged ≥30 years who had previously received two doses of inactivated COVID-19 vaccine. We collected blood samples before administering the third dose and 28 days later, and tested for antibodies to the ancestral virus using a binding assay (ELISA), a surrogate virus neutralization test (sVNT) and a live virus plaque reduction neutralization test (PRNT). We also tested for antibodies against the Omicron variant using livevirus PRNT. **Results:** In 315 participants, a third dose of BNT162b2 substantially increased antibody titers on each assay. Mean ELISA levels increased from an optical density (OD) of 0.3 to 2.2 (p<0.001), and mean sVNT levels increased from an inhibition of 17% to 96% (p<0.001). In a random subset of 20 participants, the geometric mean PRNT<sub>50</sub> titers rose very substantially by at least 24 fold from Day 0 to Day 28 against the ancestral virus (p<0.001) and rose by at least 11 fold against the Omicron variant (p<0.001). In daily monitoring, post-vaccination reactions subsided within 7 days for over 99% of participants. **Conclusions:** A third dose of COVID-19 vaccination with an mRNA vaccine substantially improved antibody levels against the ancestral virus and the Omicron variant with well-tolerated safety profile, in adults who had received two doses of inactivated vaccine 6 months earlier.

#### INTRODUCTION

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

The accrual of population immunity to COVID-19, acquired through natural infection or vaccination, will eventually bring an end to the pandemic and allow life to return to normal. Vaccine technologies being used for COVID-19 include inactivated virus, viral vectored and mRNA vaccines [1]. We have previously shown that two doses of the mRNA vaccine BNT162b2 (BioNTech/Fosun Pharma) conferred approximately 10-fold higher post-vaccination neutralising antibody titers than two doses of the aluminium hydroxide-adjuvanted inactivated virus vaccine CoronaVac (Sinovac) [2,3], while T cell responses to the two vaccines were similar [3]. The emergence of variants of concern (VOCs) and decreases in vaccine effectiveness within a few months after the second vaccine dose have resulted in recommendations for third doses [4]. Various studies have reported immunogenicity and safety of third doses using the same vaccine, i.e. homologous booster vaccination [5,6], but there are few studies evaluating heterologous booster, such as the use of a third dose of an mRNA vaccine in individuals who previously received two doses of inactivated vaccine [7-11]. Costa Clemens et al. conducted a noninferiority randomised trial of a heterologous third dose of BNT162b2 or other vaccines against a homologous third dose of CoronaVac in adults who had received two doses of CoronaVac [9]. They showed that all heterologous booster groups have substantial rise in neutralizing antibody titers (FRNT<sub>50</sub>) against the Omicron and Delta variants [9]. They also reported more local reactions but less systemic reactions to BNT162b2 compared to two adenoviral vectored vaccines given as third doses. Pérez-Then et al. reported a third dose of BNT162b2 vaccination conferred a 1.4-fold increase in neutralizing antibodies (PRNT<sub>50</sub>) against Omicron when compared to two doses of an mRNA vaccine (BNT162b2 or mRNA-1273) [8]. Here, we report a

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

trial of the immunogenicity and reactogenicity to a third dose of BNT162b2 in Chinese adults who had previously received two doses of inactivated COVID-19 vaccine. MATERIALS AND METHODS Study design The "mRNA vaccination to boost antibodies against SARS-CoV-2 in recipients of inactivated vaccines" (mBoost) study is an open-label single-arm clinical trial to measure the antibody responses and reactogenicity of an mRNA vaccine (BNT162b2) given as a third dose in adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine. CoronaVac and BNT162b2 have been available to adults in Hong Kong since March 2021. Some Hong Kong residents could have received two doses of inactivated vaccine BIBP (Sinopharm) instead from mainland China or overseas. The BNT162b2 vaccine used in Hong Kong, known as the Pfizer/BioNTech vaccine elsewhere, are distributed solely by Fosun Pharma in Greater China. Enrolment invitations were extended to community-dwelling adults in Hong Kong through mass promotion efforts including advertisements in newspapers and social media. Interested adults were invited to visit the study website and complete an online screening form for initial assessment of enrolment eligibility, and confirmed again shortly before vaccination. Individuals were eligible if they were aged ≥30 years, had previously received two doses of an inactivated COVID-19 vaccine with the most recent dose ≥90 days prior to enrolment. We excluded individuals who reported a history of COVID-19 infection, received any dose of COVID-19 vaccine other than an inactivated vaccine, or who were unsuitable to receive an mRNA vaccine

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

including but not limited to allergies to the active substance or other ingredients of the vaccine. We also excluded individuals with diagnosed medical conditions related to their immune system, use of medication that impairs immune system in the last 6 months except topical steroids or short-term oral steroids (course lasting  $\leq 14$  days), those who had used immunoglobulins or any blood products within 90 days prior to enrolment, and any females who were pregnant or intending to become pregnant in the coming 3 months. We collected 20ml clotted blood specimens at the day of enrolment and vaccination (day 0) and again after 28 days, with additional blood draws planned after 182 and 365 days. This was a single-arm study with no need for randomization, and the participants and the study staff were aware of the type of vaccination administered (no blinding). After vaccination, participants were observed for 30 minutes to record any immediate events. We then asked participants to report the presence of a list of (post-vaccination) local or systematic events/reactions daily for 7 days using an online e-diary. If the participant was still reporting any events/reaction on Day 7, additional daily monitoring continued for up to three additional weeks until symptoms resolved. On each day, participants were also asked to grade whether the reported symptoms overall have interfered with their usual activities (mild, moderate and severe). Participants are interviewed at 28, 182 and 365 days after vaccination to collect information on underlying medical conditions, and any medical encounters including hospitalizations during the study. Participants were provided with a free tympanic thermometer at enrolment, and a gift voucher of HK\$100 (US\$13) at the followup blood draws. Study data were collected and managed using REDCap electronic data capture tools [12,13].

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

**Ethics** Written informed consent was obtained from all participants. The study protocol was approved by the Institutional Review Board of the University of Hong Kong. The study was registered on Clinicaltrials.gov prior to commencement (NCT05057182). **Outcome measures** The primary outcome measure is the vaccine immunogenicity at 28 days after receipt of the third dose of BNT162b2, measured as geometric mean titer (GMT) of SARS-CoV-2 serum neutralizing antibodies against the vaccine strain (i.e. the ancestral virus) using plaque reduction neutralization test (PRNT). As the Omicron strain emerged in late 2021, we also evaluated vaccine immunogenicity against the Omicron strain. The secondary outcome measures include the GMT at other post-vaccination timepoints (i.e. at days 182 and 365) and mean-fold rises in antibody titers from baseline to each post-vaccination timepoint, and the incidence of solicited reactions or medical encounters following vaccination. Sample size justification For the primary outcome of vaccine immunogenicity, i.e. the GMT of SARS-CoV-2 serum neutralizing antibodies against the vaccine strain (ancestral virus) at 28 days after vaccination, a sample size of 300 individuals was chosen based of feasibility [14]. **Laboratory methods** Blood samples were delivered to our study laboratory at the University of Hong Kong as soon as possible, with the optimal delivery time within 24h. Sera were extracted from the clotted blood

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

within 48h and stored at -80°C until subsequent testing. We tested sera heat inactivated at 56°C for 30 minutes with three assays, our in-house enzyme-linked immunosorbent assay (ELISA) for the receptor binding domain (RBD) of the spike protein, a surrogate virus neutralisation test (sVNT) (GenScript), and a plaque reduction neutralisation test (PRNT) as previously described [11,15,16]. We aimed to tested sera collected at baseline and Day 28 with the ELISA and sVNT in all participants, and with PRNT in a randomly-selected subset of 20 participants. We have demonstrated a good correlation (r=0.77) between PRNT<sub>50</sub> and sVNT neutralization percentage for ancestral virus in our earlier studies [17]. The ELISA was not designed as a quantitative assay, although it has a dynamic range of between 0 to 5 and we have demonstrated a good correlation (r=0.83) between ELISA OD<sub>450</sub> and sVNT neutralization percentage for ancestral virus [17]. For ELISA a single 1:100 and for sVNT a single 1:10 serum dilution was tested respectively. For PRNT, a serial two-fold serum dilutions from 1:10 to 1:320 were tested. PRNT assays were carried out using ancestral SARS-CoV-2 BetaCoV/Hong Kong/VM20001061/2020 isolated in Hong Kong in January 2020 in Vero-E6 cells (ATCC CRL-1586), the Pango lineage B.1.1.529 Omicron variant designated hCoV-19/Hong Kong/VM21044713\_WHP5047-S5/2021 isolated in Vero-E6 TMRSS2 cells (Vero E6 cells overexpressing TMPRSS2, kindly provided by Dr S Matsuyama and colleagues), and the passage level 3 virus aliquots were used. Cells were maintained in DMEM medium supplemented with 10% FBS and 100 U/ml penicillinstreptomycin (all from ThermoFisher Scientific, Waltham, MA, USA). Virus sequences are available in GISAID as EPI\_ISL\_412028 and EPI\_ISL\_6716902. The PRNT<sub>50</sub> and PRNT<sub>90</sub> titers were the highest serum dilutions neutralizing  $\geq$ 50% and  $\geq$ 90% of input plaques, respectively. The WHO control serum provided by the National Institute for Biological Standards and Control

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

20/136 gave PRNT<sub>50</sub> titers of 320 and 320 against the ancestral virus and 20 and 40 against the Omicron variant in two titrations [11]. Statistical analysis We assessed the GMT of SARS-CoV-2 (PRNT) neutralizing antibody titers, surrogate virus neutralization percentages and the mean concentrations of SARS-CoV-2 Spike RBD IgG (proxy by OD<sub>450</sub>) at Day 28. For sVNT, measured negative neutralization percentages were transformed to zero. PRNT titers were taken as the reciprocal of the serum dilution and were intervalcensored, e.g. a sample that was able to neutralise virus at a 1:20 dilution but not at a 1:40 dilution was reported as 20 to indicate that the titer was  $\geq$ 20 and <40. We imputed titers <10 with the value 5 and titers  $\geq$ 320 with the value 640 for estimation of GMTs. We compared antibody levels at Day 28 after receipt of BNT162b2 to baseline using Wilcoxon signed rank tests. Correlation of PRNT<sub>90</sub> titers measured at Day 28 against the ancestral strain and the Omicron variant was estimated by Spearman's rank correlation coefficient. Reactogenicity endpoints were described as frequency (%) for local and systemic reactions or events among participants who reported health status for at least one day in the week following receipt of the third dose of BNT162b2. Statistical analyses were conducted using R version 4.1.2. **RESULTS** From 13 October 2021 through 18 January 2022 we screened 436 individuals, of which 366 (84%) were eligible and 315 (86%) were enrolled and administered BNT162b2 vaccination. We collected paired Day 0 and Day 28 blood samples in 312 (99%) vaccinated participants. Most of the participants were older Chinese adults (median aged 54 years, IQR 47-62), with 35% who

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

were obese, and about one-third reported at least one chronic medical condition including hypertension (18%), hypercholesterolemia (13%) and diabetes (7%), and almost all (98%) reported receiving two doses of CoronaVac rather than other inactivated vaccines (Table 1). Although adults who had received two doses of inactivated virus vaccination at least 90 days ago were eligible to enrol into our study (Figure S1), 75% of participants reported receiving the second dose typically around 6-7 months earlier (Table 1). A detailed flow chart of participant enrolment is provided in Figure S1. The study is ongoing and Day 182 and 365 samples will be collected in Spring 2022 and Autumn 2022 respectively. The third dose of BNT162b2 substantially increased antibody titers measured by the various assays (Figure 1). Mean ELISA levels increased from a OD of 0.3 to 2.2 (p<0.001), and mean sVNT levels increased from an inhibition of 17% to 96% (p<0.001) (Table 2). We randomly selected a subset of 20 participants for further PRNT testing against the ancestral virus and the Omicron strain (Table 1). The ELISA and sVNT levels in these 20 participants were similar to that of the 312 vaccinated participants (Figure S2). In these 20 participants, the geometric mean PRNT<sub>50</sub> titer against the ancestral strain at Day 0 was 12. We could not estimate the GMT at Day 28 because 18/20 (90%) samples were positive at the highest dilution of 1:320, and we noted that if the GMT were  $\geq$ 320 it would correspond to a mean-fold titer rise of  $\geq$ 24 from Day 0 to Day 28 (p<0.001). The geometric mean PRNT<sub>90</sub> titer against the ancestral strain at Day 0 was 6. At Day 28, 12/20 samples were positive at the highest dilution of 1:320, and we noted that if the GMT were  $\geq$ 320 it would correspond to a mean-fold titer rise of  $\geq$ 35 in PRNT<sub>90</sub> titers from Day 0 to Day 28 (p<0.001). Furthermore, in these same 20 participants the geometric mean PRNT<sub>50</sub> titer against the Omicron strain at Day 0 was 5, and rose to 59 at Day 28, a mean-fold rise of at least

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

11 given that the Day 0 titers were almost all assigned values of 5 corresponding to the floor of the assay at <10 (p<0.001). The geometric mean PRNT<sub>90</sub> titer against the Omicron strain at Day 0 was also 5, and rose to 19 at Day 28, a mean-fold rise of at least 3 (p<0.001). We did not identify any evidence that suggest a correlation between the PRNT<sub>90</sub> titers against the Omicron variant and that against the ancestral virus (r=0.30, p=0.21) (Figure S3). Among the 315 participants who received BNT162b2 vaccination, 304 (97%) participants reported health status for at least one day in the week following receipt of BNT162b2, including 234 (77%) who reported every day and another 38 (13%) reported for  $\geq$ 7 days. 193/304 (63%) participants reported feeling unwell for an average of 2.9 days (SD 1.8 days), and only 3 (<1%) participants reported feeling unwell beyond 7 days after third-dose BNT162b2 vaccination. Within the 7 days after receipt of BNT162b2, the most commonly reported local reactions were pain (46%) and tenderness (44%) at the injection site, while systemic reactions were reported by a minority of participants (Table 3). These symptoms usually subsided within 7 days after vaccination (Figure 2). Among 312 participants whose information is available, 6 (2%) reported having sought medical consultation within one month of the third dose but none were hospitalized. Among these 6 participants, 4 reported seeking medical consultation possibly for discomfort associated with vaccination within the week after vaccination, and the remaining two participants sought medical consultation due to back pain or stress outside the 7-day window. **DISCUSSION** Work by our research group and others indicates that two doses of inactivated COVID-19 vaccine confer moderate increases in antibody levels at one month after the second dose [2, 3].

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

Antibody levels then gradually decline, but can be boosted by receipt of third doses. Zeng et al. reported that a third dose of inactivated vaccine given to healthy young adults at 8 months after the second dose of the same vaccine boosted neutralizing antibodies against the ancestral strain by about 21-fold [5]. Here, we show that a third dose of mRNA vaccine (BNT162b2) after two doses of inactivated virus vaccine (mostly CoronaVac), all originally formulated against the ancestral virus, boosted PRNT<sub>50</sub> titers against the ancestral strain by a factor of at least 27-fold. Similarly, Clemens et al. showed that a third dose of mRNA or adenoviral vectored vaccines induced greater rises in anti-Spike binding antibodies compared to a third dose of inactivated vaccine among CoronaVac recipients [9]. Both suggest a substantial improvement of heterologous boosting using mRNA vaccine over homologous boosting using inactivated vaccine against the ancestral virus. We also show that a third dose of BNT162b2 conferred substantial rises in PRNT<sub>50</sub> titers against the Omicron variant. While there is still a lack of consensus on the antibody threshold for protection [18-21], the PRNT<sub>50</sub> titers against Omicron at Day 28 in our study are higher than the PRNT<sub>50</sub> titers against ancestral virus after two doses of CoronaVac where the geometric mean PRNT<sub>50</sub> titer was estimated to be 27 [2]. Given that two doses of inactivated vaccine were estimated to provide at least 50% protection against infection with the ancestral virus [22-24], the antibody levels against Omicron estimated in our study could correspond to a moderate degree of effectiveness in protection against Omicron. Most of the participants in our study were older adults, and their antibody levels against Omicron were at a very low level at Day 0 prior to the third dose, consistent with other recent studies [8,9]. Almost one-third of participants had underlying medical conditions (Table 1). In our separate initial investigation which included sera from individuals with various intervals (51-234

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

days) between second and third dose [11] and some of whom were selected for third dose vaccination due to low (<60%) post-second dose serum surrogate neutralizing antibodies [25], we showed that administering BNT162b2 about 3 months after two doses of CoronaVac reported a GMT of 59 against Omicron compared to 305 against the ancestral virus after the boost [11]. Costa Clemens et al. showed that heterologous boosting with third dose of mRNA or adenoviral vectored vaccines induced greater rise in neutralising antibodies against both Omicron and Delta variants than homologous boosting with inactivated vaccines [9]. Together, these studies suggest the substantial boost in neutralizing antibody titers against both the ancestral virus and Omicron variant by a heterologous third dose of mRNA vaccination will clearly improve protection against the Omicron strain (and potentially other variant strains). Earlier studies have investigated post-vaccination reactions after two or three doses of inactivated [5, 23, 26] or mRNA vaccination [27,28]. These studies suggest fatigue, myalgia and chill were common both after receipt of inactivated [23] or mRNA vaccines [27]; nausea was common after inactivated vaccination [23]; and fever and headache after mRNA vaccination [27]. Similar to reactions after mRNA vaccination, feverishness and headache were commonly reported in our study while gastrointestinal symptoms such as nausea and diarrhoea were less commonly reported. No hospitalization was reported within the month after vaccination in our study, although our sample size would not have been large enough to detect rare events. Our study had several limitations. We have only performed PRNT against ancestral strain and Omicron variant up to a dilution of 1:320. However, more than half of our study participants were positive for antibodies to the ancestral strain at this dilution indicating antibody titers  $\geq 320$ ,

and we were therefore not able to determine exactly the GMT against ancestral strain after the third dose of vaccination but only confirm that it was likely ≥320. Similarly, Day 0 samples were typically negative even at the starting dilution of 1:10, limiting our assessment of pre-vaccination GMTs. Nevertheless, we were able to conclude that third dose of mRNA vaccination would provide substantial benefits against both ancestral and Omicron strains. Our results on immunogenicity may be subjected to selection bias including volunteer bias, since in Hong Kong older adults are more inclined to receive the inactivated vaccines and younger adults to mRNA vaccines [29]. Our results on reactogenicity may be subjected to information bias as this was an open-label trial and it is recognized that there could be more post-vaccination reactions after mRNA vaccination compared to inactivated vaccination [30].

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

References 1. Subbarao K. The success of SARS-CoV-2 vaccines and challenges ahead. Cell Host Microbe **2021**; 29(7): 1111-23. 2. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2021; 2(9): e423. Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of 3. BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 2022; 27(4): 301-10. 4. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med **2021**; 385(15): 1393-400. 5. Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis **2022**; 22(4): 483-95. 6. Falsey AR, Frenck RW, Jr., Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med 2021; 385(17): 1627-9. Intapiboon P, Seepathomnarong P, Ongarj J, et al. Immunogenicity and Safety of an 7. Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population. Vaccines (Basel) **2021**; 9(12): 1375. 8. Perez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2

booster vaccination. Nat Med **2022**; 28(3): 481-5.

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

9. Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet **2022**; 399(10324): 521-9. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-10. 19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet **2021**; 398(10318): 2258-76. 11. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med **2022**; 28(3): 486-9. 12. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform **2009**; 42(2): 377-81. 13. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95: 103208. 14. World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. Geneva, Switzerland, 2017. 15. Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill **2020**; 25(16).

338 16. Perera R, Ko R, Tsang OTY, et al. Evaluation of a SARS-CoV-2 Surrogate Virus 339 Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. 340 J Clin Microbiol **2021**; 59(2). 341 17. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing 342 antibody responses after infection and estimates of the duration of protection. 343 EClinicalMedicine **2021**; 41: 101174. 344 18. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective 345 correlate for COVID-19 vaccines. Vaccine 2021; 39(32): 4423-8. 346 19. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and 347 asymptomatic SARS-CoV-2 infection. Nat Med **2021**; 27(11): 2032-40. 348 20. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the 349 mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022; 375(6576): 43-50. 350 21. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly 351 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 352 **2021**; 27(7): 1205-11. 353 Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on 22. Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA 2021; 354 355 326(1): 35-45. 356 23. Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated 357 whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, 358 randomised, placebo-controlled, phase 3 trial in Turkey. Lancet **2021**; 398(10296): 213-359 22.

Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat 360 24. 361 Med **2021**; 27(2): 205-11. 362 25. Mok CKP, Cheng SMS, Chen C, et al. A RCT Using CoronaVac or BNT162b2 Vaccine 363 as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac. Am J Respir Crit 364 Care Med **2022**. 365 Cao Y, Hao X, Wang X, et al. Humoral immunogenicity and reactogenicity of 26. 366 CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Res 2022; 367 32(1): 107-9. 368 27. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA 369 Covid-19 Vaccine. N Engl J Med **2020**; 383(27): 2603-15. 370 28. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant 371 mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med **2021**; 27(11): 372 2025-31. 373 McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of two and three doses of 29. 374 BNT162b2 and CoronaVac against COVID-19 in Hong Kong. [Preprint]. Available 375 from: https://www.medrxiv.org/content/10.1101/2022.03.22.22272769v2. 376 30. McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative 377 systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of 378 vaccines against SARS-CoV-2. NPJ Vaccines **2021**; 6(1): 74. 379 380

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

Acknowledgements We gratefully acknowledge colleagues including Eileen Yu, Teresa So and Zacary Chai for technical support in preparing and conducting this study; Anson Ho for setting up the database; Julie Au and Lilly Wang for administrative support; Hetti Cheung, Victoria Wong, Bobo Yeung at HKU Health System; Cindy Man and other colleagues at the HKU Community Vaccination Centres at Gleneagles Hospital; and all the study participants for facilitating the study. **Funding** This project was supported by the Theme-based Research Scheme T11-712/19-N of the Research Grants Council of the Hong Kong Special Administrative Region, China (BJC). BJC is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript. **Author contributions** All authors meet the ICMJE criteria for authorship. Each author's contributions to the paper are listed below according to the CRediT model: Conceptualization: NHLL, GML, BJC Methodology: NHLL, SMSC Formal analysis: NHLL, MM-S Investigation: NYMA, YYN, LLHL, KCKC, JKCL, YWYL, LCHT, SC, KKHK Funding acquisition: BJC

Project administration: NHLL, SMSC, JSMP, BJC

Supervision: NHLL, SMSC, DKMI, LLMP, GML, JSMP, BJC

Writing – original draft: NHLL, MM-S, JSMP, BJC

Writing – review & editing: NHLL, SMSC, MM-S, NYMA, YYN, LLHL, KCKC, JKCL, YWYL, LCHT, SC, KKHK, DKMI, LLMP, GML, JSMP, BJC.

Competing interests

BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no other potential conflicts of interest.

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

FIGURE LEGENDS Figure 1. Third dose of SARS-CoV-2 BNT162b2 vaccine boosts serum antibodies against ancestral strain and Omicron variant in adults who previously received two doses of inactivated vaccines. (A) ELISA for serum IgG against SARS-CoV-2 Spike receptor binding domain (RBD) of ancestral strain. (B) Surrogate virus neutralization test (sVNT) against ancestral strain. Live virus plaque reduction neutralization test (PRNT) against ancestral strain with endpoints at (C) 50% (PRNT<sub>50</sub>) or (D) 90% (PRNT<sub>90</sub>). Live virus plaque reduction neutralization test (PRNT) against Omicron variant with endpoints at (E) 50% (PRNT<sub>50</sub>) or (F) 90% (PRNT<sub>90</sub>). X in each panel indicates the median level. Data for ELISA and sVNT were available from 312 vaccinated participants whom paired day 0 and day 28 sera were collected, while data for PRNT were available from a random sample of 20 participants. Figure 2. Solicited local and systemic reactions during the 7 days after third dose BNT162b2 vaccination in adults who previously received two doses of inactivated COVID-**19 vaccine.** \*For solicited systemic reactions, only feverish/fever ≥ 38.0°C/ chills, and those reported in at least 10% of participants are shown. Figure S1. Flow chart for this single-arm, open-label clinical trial of BNT162b2 provided as a third vaccine dose in adults who previously received two doses of inactivated COVID-19 vaccine.

Figure S2. ELISA and sVNT antibody levels in 20 participants randomly selected to be tested by PRNT compared to all vaccinated participants with paired Day 0 and Day 28 sera collected. (A) ELISA for serum IgG against SARS-CoV-2 Spike receptor binding domain (RBD) of ancestral strain. (B) Surrogate virus neutralization test (sVNT) against ancestral strain. X indicates the mean level. All: all vaccinated participants with paired Day 0/ Day 28 sera collected (N = 312); Selected: participants randomly selected to be tested by PRNT (N = 20).

Figure S3. Correlation of PRNT<sub>90</sub> titers measured at Day 28 against ancestral strain and the Omicron variant in 20 participants randomly selected for performing PRNT. PRNT titers are measured based on two-fold dilutions and plotted here within an interval, or <10 (plotted on axis) or ≥320 (plotted above 320). r: Spearman's rank correlation coefficient; p: p-value.

**Table 1. Characteristics of study participants at baseline.** We enrolled and administered BNT162b2 vaccine as a third vaccine dose in 315 adults who previously received two doses of inactivated COVID-19 vaccine. Among them, ELISA and sVNT against ancestral SARS-CoV-2 virus were performed in paired Day 0 and Day 28 sera available from 312 vaccinated participants, and we randomly selected 20 participants to also perform PRNT against ancestral SARS-CoV-2 virus and the Omicron variant. ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque reduction neutralisation test.

Characteristic	Participants tested by ELISA & sVNT	Random subset of 20 participants tested by ELISA, sVNT & PRNT		
	(N = 312)	(N = 20)		
	n (%)	n (%)		
Female	120 (38)	9 (45)		
Age (median, IQR)	54 (47-62)	55 (47-64)		
Ethnicity				
Chinese	306 (98)	20 (100)		
Obesity (for Asian populations)				
Underweight (BMI < 18.5)	6 (2)	0 (0)		
Normal (BMI 18.5 – 22.9)	114 (37)	5 (25)		
Overweight (BMI 23.0 – 24.9)	84 (27)	7 (35)		
Obese (BMI $\geq$ 25.0)	108 (35)	8 (40)		
Chronic medical conditions				
Any	98 (32)	6 (30)		
Lung disease, including COPD and asthma	1 (0)	0 (0)		
Heart disease	7 (2)	0 (0)		
Hypertension	57 (18)	5 (25)		
Diabetes	22 (7)	1 (5)		
Hypercholesterolemia	42 (13)	3 (15)		
Kidney disease	4(1)	0 (0)		
Liver disease	4(1)	1 (5)		
Cancer	5 (2)	1 (5)		
Prior COVID-19 vaccination				
2-dose CoronaVac (Sinovac)	305 (98)	20 (100)		
2-dose BIBP (Sinopharm)	7 (2)	0 (0)		
Days between first and second dose of COVID-19 vaccination (median, IQR)	28 (28-29)	28 (28-29)		
Days between second and third (study) dose of	206 (192-217)	197 (172-208)		

### COVID-19 vaccination (median, IQR)

## **Smoking**

Ever	33 (11)	5 (25)
Current	22 (7)	3 (15)

**Table 2.** Antibody response after third dose BNT162b2 vaccination in adults who previously received two doses of inactivated COVID-19 vaccine. ELISA and sVNT against ancestral SARS-CoV-2 virus were performed in paired Day 0 and Day 28 sera available from 312 vaccinated participants, and we randomly selected 20 participants to also perform PRNT against ancestral SARS-CoV-2 virus and the Omicron variant. Significant differences between antibody level at Day 0 and Day 28 was evaluated by Wilcoxon signed rank tests. ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque reduction neutralisation test; GMT: geometric mean titer.

	Participants t	ested by ELISA &	k sVNT	Participants tested by ELISA, sVNT & PRNT				
		(N = 312)		(N=20)				
	Day 0	Day 28	p-value	Day 0	Day 28	p-value		
Ancestral ELISA								
Mean (SD)	0.3 (0.2)	2.2 (0.4)	-0.001	0.3 (0.3)	2.0 (0.3)	-0.001		
Median (IQR)	0.2 (0.2-0.4)	2.0 (1.9-2.5)	< 0.001	0.2 (0.2-0.3)	1.9 (1.8-2.0)	< 0.001		
Ancestral sVNT								
Mean (SD)	17% (16)	96% (3)	< 0.001	21% (16)	97% (1)	رم مرد 1 مرد م		
Median (IQR)	13% (5-23)	97% (96-97)	<0.001	21% (6-32)	97% (97-97)	< 0.001		
Ancestral PRNT <sub>50</sub>								
GMT (SD)				12 (2)	557 (2)			
Median (IQR)		N/A		10 (5-20)	≥320 (≥320-≥320)	< 0.001		
Ancestral PRNT <sub>90</sub>								
GMT (SD)				6 (1)	309 (3)			
Median (IQR)		N/A		5 (5-5)	≥320 (160-≥320)	< 0.001		
Omicron PRNT <sub>50</sub>								
GMT (SD)	N/A			5 (1)	59 (4)	< 0.001		
Median (IQR)		IV/A		5 (5-5)	40 (20-100)	\0.001		
Omicron PRNT <sub>90</sub>								
GMT (SD)	NT/A			5 (1)	19 (3)	< 0.001		
Median (IQR)		N/A		5 (5-5)	15 (10-40)	<0.001		

Footnote: For the estimation of GMT for PRNT<sub>50</sub> and PRNT<sub>90</sub> titers, titers <10 were imputed as 5 and titers  $\ge$ 320 were imputed as 640.


Table 3. Solicited local and systemic reactions on the day after and anytime within 7 days after third dose BNT162b2 vaccination in adults who previously received two doses of inactivated COVID-19 vaccine. Daily frequencies within 7 days after third dose BNT162b2 vaccination for reactions highlighted in bold are shown in Figure 2.

Post-vaccination reactions	Anytime within 7 days after third dose BNT162b2 vaccination (N = 304)	Day 1 after third dose BNT162b2 vaccination (N = 304) n (%)			
	n (%)				
Local reactions at the injection		H (70)			
Pain*	141 (46)	130 (43)			
Tenderness*	133 (44)	108 (36)			
Swelling or hardness*	71 (23)	51 (17)			
Itchiness*	20 (7)	2(1)			
Redness*	15 (5)	5 (2)			
Systemic reactions and ger	neral symptoms				
Feverish	72 (24)	55 (18)			
Fever $\geq 38.0^{\circ}$ C	26 (9)	20 (7)			
Chills	32 (11)	29 (10)			
Headache	75 (25)	56 (18)			
Myalgia	54 (18)	38 (12)			
Fatigue	<b>56</b> (18)	42 (14)			
Drowsiness	51 (17)	38 (12)			
Malaise	31 (10)	20 (7)			
Pain at the injection arm	25 (8)	14 (5)			
Loss of appetite	21 (7)	12 (4)			
Dizziness	21 (7)	11 (4)			
Runny nose	20 (7)	12 (4)			
Nasal congestion	19 (6)	9 (3)			
Arthralgia	17 (6)	10 (3)			
Sneezing	17 (6)	8 (3)			
Sore throat	17 (6)	10 (3)			
Chest discomfort	13 (4)	9 (3)			
Diarrhoea	13 (4)	4 (1)			
Abdominal distention	11 (4)	6 (2)			
Palpitations	11 (4)	5 (2)			
Insomnia	11 (4)	5 (2)			
Phlegm	10 (3)	5 (2)			
Nausea	9 (3)	5 (2)			
Cough	8 (3)	4 (1)			
Abdominal pain	7 (2)	4 (1)			
Constipation	6 (2)	4 (1)			
Body itching	5 (2)	2 (1)			
Flushing of the face	4(1)	3 (1)			
Skin rash	3(1)	1 (0)			
Chest pain	3(1)	0 (0)			
Enlarged lymph nodes	3 (1)	0 (0)			
Face swelling	2(1)	0 (0)			
Arm or leg swelling	1 (0)	1 (0)			
Muscle spasms	1 (0)	1 (0)			
Confusion	1 (0)	1 (0)			


Dyspnea	1 (0)	0 (0)
Nosebleeds	0 (0)	0 (0)
Ageusia	0 (0)	0 (0)
Anosmia	0 (0)	0 (0)
Conjunctivitis	0 (0)	0 (0)
Vomiting	0 (0)	0 (0)
Facial drooping/	0 (0)	0 (0)
weakness		
Loss of consciousness	0 (0)	0 (0)
Seizure	0 (0)	0 (0)

Supplementary Table 1. Antibody levels measured by ELISA, sVNT and PRNT against ancestral SARS-CoV-2 virus and the Omicron variant at Day 0 and 28 after third-dose BNT162b2 vaccination, in 20 randomly selected participants who previously received two doses of inactivated COVID-19 vaccine. D0: Day 0 (baseline); D28: Day 28 (post-vaccination); ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque reduction neutralisation test; PRNT<sub>50</sub>: 50% plaque reduction neutralization titer; PRNT<sub>90</sub>: 90% plaque reduction neutralization titer


	Ancestral SARS-CoV-2 virus								Omicron variant			
	ELISA Spike RBD IgG (OD <sub>450</sub> )		sVNT % inhibition (%)		PRNT <sub>50</sub> titer		PRNT <sub>90</sub> titer		PRNT <sub>50</sub> titer		PRNT <sub>90</sub> titer	
	D0	D28	<b>D</b> 0	D28	D0	<b>D28</b>	<b>D</b> 0	D28	<b>D</b> 0	D28	<b>D</b> 0	D28
1	0.2	1.7	20	94	<10	160	<10	40	<10	<10	<10	<10
2	0.1	2.6	0	97	<10	≥320	<10	≥320	<10	10	<10	<10
3	1.2	1.9	6	97	<10	≥320	<10	160	<10	20	<10	10
4	0.1	1.9	3	97	<10	≥320	<10	160	<10	40	<10	10
5	0.2	1.9	14	97	<10	≥320	<10	160	<10	80	<10	40
6	0.3	2.0	30	97	<10	≥320	<10	≥320	<10	80	<10	20
7	0.1	1.8	0	96	10	160	<10	40	<10	20	<10	10
8	0.2	2.7	23	97	10	≥320	<10	≥320	<10	20	<10	10
9	0.7	1.5	42	97	10	≥320	<10	≥320	<10	40	<10	10
10	0.2	1.9	0	97	10	≥320	<10	≥320	<10	40	<10	10
11	0.5	1.7	48	91	10	≥320	<10	≥320	<10	160	<10	40
12	0.2	2.1	19	98	10	≥320	<10	80	<10	≥320	<10	160
13	0.2	1.8	23	97	20	≥320	<10	160	<10	20	<10	<10
14	0.2	1.7	28	97	20	≥320	<10	160	<10	40	<10	10
15	0.2	1.9	6	97	20	≥320	<10	≥320	<10	≥320	<10	80
16	0.2	2.0	5	97	20	≥320	<10	≥320	10	40	<10	20
17	0.4	1.7	37	97	40	≥320	10	≥320	<10	80	<10	20
18	0.2	2.8	29	97	40	≥320	10	≥320	<10	80	<10	20
19	0.7	2.0	44	97	40	≥320	10	≥320	<10	160	<10	40
20	0.2	1.9	36	97	40	≥320	10	≥320	<10	≥320	<10	160



# Solicited local reactions



# Solicited systemic reactions\*



- Did not have prior COVID-19 infection
- Did not have medical conditions related to immune system
- Did not use immunosuppressant in the last 6 months
- etc.

